Determination of Severity of Murine IgA Nephropathy by Glomerular Complement Activation by Aberrantly Glycosylated IgA and Immune Complexes
Overview
Authors
Affiliations
The pathogenic roles of glomerular deposition of components of the complement cascade in IgA nephropathy (IgAN) are not completely clarified. To investigate the pathologic role of complement pathways in IgAN, two IgAN-prone mouse models were examined. Grouped ddY (gddY) mice showed significant high proteinuria, severe glomerular lesions, and extracellular matrix expansion compared with high serum IgA (HIGA) mice but with similar intensity of glomerular IgA deposition. Glomerular activation of the classical, lectin, and alternative pathways was demonstrated by significantly stronger staining for complement (C)3, C5b-9, C1q, C4, mannose-binding lectin (MBL)-A/C, MBL-associated serine protease-2, and factor B and properdin in gddY mice than in HIGA mice. Similarly, the serum levels of IgA-IgG2a/IgM and IgA-MBL-A/C immune complexes and polymeric IgA were significantly higher in gddY mice than in HIGA mice. Moreover, the serum levels of aberrantly glycosylated IgA characterized by the binding of Sambucus nigra bark lectin and Ricinus communis agglutinin I were significantly higher in gddY mice than in HIGA mice. This aberrancy in glycosylation was confirmed by monosaccharide compositional analysis of purified IgA using gas-liquid chromatography. This study is the first to demonstrate that aberrantly glycosylated IgA may influence the formation of macromolecular IgA including IgA-IgG immune complexes and subsequent complement activation, leading to full progression of IgAN.
Lessons from IgA Nephropathy Models.
Kano T, Suzuki H, Makita Y, Nihei Y, Fukao Y, Nakayama M Int J Mol Sci. 2024; 25(21).
PMID: 39519036 PMC: 11546737. DOI: 10.3390/ijms252111484.
Targeting the Endothelin A Receptor in IgA Nephropathy.
Kohan D, Barratt J, Heerspink H, Campbell K, Camargo M, Ogbaa I Kidney Int Rep. 2023; 8(11):2198-2210.
PMID: 38025243 PMC: 10658204. DOI: 10.1016/j.ekir.2023.07.023.
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
Mathur M, Barratt J, Chacko B, Chan T, Kooienga L, Oh K N Engl J Med. 2023; 390(1):20-31.
PMID: 37916620 PMC: 7615905. DOI: 10.1056/NEJMoa2305635.
Crescents and IgA Nephropathy: A Delicate Marriage.
Trimarchi H, Haas M, Coppo R J Clin Med. 2022; 11(13).
PMID: 35806856 PMC: 9267724. DOI: 10.3390/jcm11133569.
Trimarchi H Pediatr Nephrol. 2021; 37(6):1205-1214.
PMID: 34312722 DOI: 10.1007/s00467-021-05199-1.